5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: a pediatric oncology group phase I-II study.
Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5-fluorouracil (5-FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.
D000293:Adolescent; D000328:Adult; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*
D002945:Cisplatin; D005472:Fluorouracil